FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045200321> ?p ?o ?g. }

• W2045200321 endingPage "2247" @default.
• W2045200321 startingPage "2247" @default.
• W2045200321 abstract "HER2-amplified (HER2 + ) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2 + tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully, particularly in trastuzumab-resistant tumors. We used mouse models of trastuzumab sensitive and trastuzumab-resistant HER2 + breast cancers to measure dynamic changes in tumor microvessel density and hemoglobin oxygenation (sO2) in vivo using quantitative hyperspectral imaging at 2, 5, 9, and 14 days after antibody treatment. Further analysis quantified the distribution of microvessels into low and high oxygenation groups, and monitored changes in these distributions with trastuzumab treatment. Gold standard immunohistochemistry was performed to validate complementary markers of tumor cell and vascular response to treatment. Trastuzumab treatment in both responsive and resistant tumors resulted in decreased sO2 5 days after initial treatment when compared to IgG-treated controls (p<0.05). Importantly, responsive tumors showed significantly higher vessel density and significantly lower sO2 than all other groups at 5 days post-treatment (p<0.05). Distribution analysis of vessel sO2 showed a significant (p<0.05) shift of highly oxygenated vessels towards lower oxygenation over the time-course in both trastuzumab-treated responsive and resistant tumors. This study suggests that longitudinal hyperspectral imaging of microvessel sO2 and density could distinguish trastuzumab-responsive from trastuzumab-resistant tumors, a finding that could be exploited in the post-neoadjuvant setting to guide post-surgical treatment decisions." @default.
• W2045200321 created "2016-06-24" @default.
• W2045200321 creator A5011699023 @default.
• W2045200321 creator A5020742692 @default.
• W2045200321 creator A5037945408 @default.
• W2045200321 creator A5043946489 @default.
• W2045200321 creator A5055160495 @default.
• W2045200321 creator A5084628898 @default.
• W2045200321 creator A5085677036 @default.
• W2045200321 date "2014-06-16" @default.
• W2045200321 modified "2023-09-25" @default.
• W2045200321 title "In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts" @default.
• W2045200321 cites W1551111627 @default.
• W2045200321 cites W1783580437 @default.
• W2045200321 cites W1910255636 @default.
• W2045200321 cites W1969664442 @default.
• W2045200321 cites W1980642669 @default.
• W2045200321 cites W1989560325 @default.
• W2045200321 cites W1992560794 @default.
• W2045200321 cites W2006202974 @default.
• W2045200321 cites W2010545060 @default.
• W2045200321 cites W2015285868 @default.
• W2045200321 cites W2031695016 @default.
• W2045200321 cites W2034801324 @default.
• W2045200321 cites W2053848912 @default.
• W2045200321 cites W2061851135 @default.
• W2045200321 cites W2068554135 @default.
• W2045200321 cites W2073844962 @default.
• W2045200321 cites W2074196937 @default.
• W2045200321 cites W2080518844 @default.
• W2045200321 cites W2095156669 @default.
• W2045200321 cites W2105398998 @default.
• W2045200321 cites W2112154408 @default.
• W2045200321 cites W2115759102 @default.
• W2045200321 cites W2118439356 @default.
• W2045200321 cites W2121388227 @default.
• W2045200321 cites W2132907499 @default.
• W2045200321 cites W2136348963 @default.
• W2045200321 cites W2142635246 @default.
• W2045200321 cites W2143738177 @default.
• W2045200321 cites W2145388473 @default.
• W2045200321 cites W2149908785 @default.
• W2045200321 cites W2161428561 @default.
• W2045200321 cites W274351828 @default.
• W2045200321 cites W4239989216 @default.
• W2045200321 doi "https://doi.org/10.1364/boe.5.002247" @default.
• W2045200321 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4102362" @default.
• W2045200321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25071962" @default.
• W2045200321 hasPublicationYear "2014" @default.
• W2045200321 type Work @default.
• W2045200321 sameAs 2045200321 @default.
• W2045200321 citedByCount "34" @default.
• W2045200321 countsByYear W20452003212015 @default.
• W2045200321 countsByYear W20452003212016 @default.
• W2045200321 countsByYear W20452003212017 @default.
• W2045200321 countsByYear W20452003212018 @default.
• W2045200321 countsByYear W20452003212019 @default.
• W2045200321 countsByYear W20452003212020 @default.
• W2045200321 countsByYear W20452003212021 @default.
• W2045200321 countsByYear W20452003212022 @default.
• W2045200321 countsByYear W20452003212023 @default.
• W2045200321 crossrefType "journal-article" @default.
• W2045200321 hasAuthorship W2045200321A5011699023 @default.
• W2045200321 hasAuthorship W2045200321A5020742692 @default.
• W2045200321 hasAuthorship W2045200321A5037945408 @default.
• W2045200321 hasAuthorship W2045200321A5043946489 @default.
• W2045200321 hasAuthorship W2045200321A5055160495 @default.
• W2045200321 hasAuthorship W2045200321A5084628898 @default.
• W2045200321 hasAuthorship W2045200321A5085677036 @default.
• W2045200321 hasBestOaLocation W20452003211 @default.
• W2045200321 hasConcept C121608353 @default.
• W2045200321 hasConcept C126322002 @default.
• W2045200321 hasConcept C142724271 @default.
• W2045200321 hasConcept C150903083 @default.
• W2045200321 hasConcept C159654299 @default.
• W2045200321 hasConcept C203014093 @default.
• W2045200321 hasConcept C204232928 @default.
• W2045200321 hasConcept C207001950 @default.
• W2045200321 hasConcept C2776436680 @default.
• W2045200321 hasConcept C2779786085 @default.
• W2045200321 hasConcept C502942594 @default.
• W2045200321 hasConcept C530470458 @default.
• W2045200321 hasConcept C542903549 @default.
• W2045200321 hasConcept C71924100 @default.
• W2045200321 hasConcept C86803240 @default.
• W2045200321 hasConceptScore W2045200321C121608353 @default.
• W2045200321 hasConceptScore W2045200321C126322002 @default.
• W2045200321 hasConceptScore W2045200321C142724271 @default.
• W2045200321 hasConceptScore W2045200321C150903083 @default.
• W2045200321 hasConceptScore W2045200321C159654299 @default.
• W2045200321 hasConceptScore W2045200321C203014093 @default.
• W2045200321 hasConceptScore W2045200321C204232928 @default.
• W2045200321 hasConceptScore W2045200321C207001950 @default.
• W2045200321 hasConceptScore W2045200321C2776436680 @default.
• W2045200321 hasConceptScore W2045200321C2779786085 @default.
• W2045200321 hasConceptScore W2045200321C502942594 @default.
• W2045200321 hasConceptScore W2045200321C530470458 @default.
• W2045200321 hasConceptScore W2045200321C542903549 @default.

• next